Drugs / buprenorphine/naloxone
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05062577 Background | Nov 2021 → Feb 2023 | substance-related disorder | Astellas Pharma Global Development, Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | buprenorphine/naloxone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05062577 ↗ |